FR2985428B1 - Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue - Google Patents

Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue

Info

Publication number
FR2985428B1
FR2985428B1 FR1250223A FR1250223A FR2985428B1 FR 2985428 B1 FR2985428 B1 FR 2985428B1 FR 1250223 A FR1250223 A FR 1250223A FR 1250223 A FR1250223 A FR 1250223A FR 2985428 B1 FR2985428 B1 FR 2985428B1
Authority
FR
France
Prior art keywords
polyaminoacide
substituted
injectable solution
basic insulin
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1250223A
Other languages
English (en)
Other versions
FR2985428A1 (fr
Inventor
Olivier Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1250223A priority Critical patent/FR2985428B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to PCT/FR2013/050043 priority patent/WO2013104861A1/fr
Priority to CN202111083637.8A priority patent/CN113730555A/zh
Priority to BR112014016889A priority patent/BR112014016889A8/pt
Priority to EP13701849.5A priority patent/EP2814461B1/fr
Priority to CN201710727572.3A priority patent/CN107583039A/zh
Priority to US13/737,353 priority patent/US9198971B2/en
Priority to CN201380009297.1A priority patent/CN104114155B/zh
Publication of FR2985428A1 publication Critical patent/FR2985428A1/fr
Priority to US14/922,663 priority patent/US10335489B2/en
Application granted granted Critical
Publication of FR2985428B1 publication Critical patent/FR2985428B1/fr
Priority to HK18108633.6A priority patent/HK1248607A1/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1250223A 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue Expired - Fee Related FR2985428B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1250223A FR2985428B1 (fr) 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
CN201380009297.1A CN104114155B (zh) 2012-01-09 2013-01-09 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
BR112014016889A BR112014016889A8 (pt) 2012-01-09 2013-01-09 composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
EP13701849.5A EP2814461B1 (fr) 2012-01-09 2013-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
CN201710727572.3A CN107583039A (zh) 2012-01-09 2013-01-09 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
US13/737,353 US9198971B2 (en) 2012-01-09 2013-01-09 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
PCT/FR2013/050043 WO2013104861A1 (fr) 2012-01-09 2013-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
CN202111083637.8A CN113730555A (zh) 2012-01-09 2013-01-09 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
US14/922,663 US10335489B2 (en) 2012-01-09 2015-10-26 Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
HK18108633.6A HK1248607A1 (zh) 2012-01-09 2018-07-04 Ph為7且至少含pi為5．8至8．5之基礎胰島素和取代共聚(氨基酸)的可注射溶液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250223A FR2985428B1 (fr) 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue

Publications (2)

Publication Number Publication Date
FR2985428A1 FR2985428A1 (fr) 2013-07-12
FR2985428B1 true FR2985428B1 (fr) 2016-05-27

Family

ID=46420325

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1250223A Expired - Fee Related FR2985428B1 (fr) 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue

Country Status (1)

Country Link
FR (1) FR2985428B1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101810055B1 (ko) 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
US9198971B2 (en) 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (fr) * 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
FR3074422B1 (fr) * 2017-12-06 2021-11-19 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) * 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3074681B1 (fr) * 2017-12-07 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) * 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3723728A1 (fr) 2017-12-07 2020-10-21 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
TWI813604B (zh) 2017-12-07 2023-09-01 法商阿道洽公司 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液
MX2020005916A (es) * 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
US11129877B2 (en) 2017-12-07 2021-09-28 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
EP3740195A1 (fr) 2017-12-07 2020-11-25 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020005913A (es) * 2017-12-07 2020-10-19 Adocia Solución inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
WO2020245470A1 (fr) * 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
AU2003294056A1 (en) * 2002-12-04 2004-07-29 Flamel Technologies Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2902007B1 (fr) * 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
PL2209800T3 (pl) * 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins

Also Published As

Publication number Publication date
FR2985428A1 (fr) 2013-07-12

Similar Documents

Publication Publication Date Title
FR2985428B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
HK1254856A1 (zh) 泵，特別是血液泵
IL240285A0 (en) Biomarkers for type ii diabetes and their uses
JP2013241444A5 (fr)
EP2967344A4 (fr) Dispositifs, systèmes et procédés associés à des dispositifs de surveillance d'analyte, et dispositifs comprenant lesdits dispositifs de surveillance d'analyte
JP2015520632A5 (fr)
FR2985429B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
IT1398142B1 (it) Sistema singolo con compressore e pompa integrati e metodo.
FR3003196B1 (fr) Vitrage comprenant un ecran transparent.
FR2994044B1 (fr) Procede d'affichage auto-stereoscopique sur un ecran ayant sa plus grande dimension dans le sens vertical.
FR3007815B1 (fr) Connecteur fluidique avec verrouillage.
FR3001607B1 (fr) Semoir monograine avec au moins un element semeur perfectionne
BR112015026191A2 (pt) barra de reforço, conjunto de conduto de fluxo, e, método para montar um medidor de fluxo vibratório.
DK2994641T3 (da) Magnetkoblingspumpearrangement.
FR3002293B1 (fr) Pompe a precompression amelioree.
JP2014071113A5 (fr)
FR2978918B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5
FR3029958B1 (fr) Dispositif d'entrainement d'un vantail coulissant dans un dormant.
JP2015521279A5 (fr)
Statistics SPSS statistics
FR3006635B1 (fr) Element de garnissage comprenant au moins un element de detection
FR3002911B1 (fr) Renfort superieur de custode avec renvoi de sangle.
FR3006728B1 (fr) Roulement a rotule comprenant des joints d'etancheite.
GB2520055B (en) Retaining member and saw horse assembly comprising a retaining member
ES1086204Y (es) Cuadro para bicicleta.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20210905